All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

IL inhibitors

IL inhibitors

Interleukin (IL) pathways have been found to be involved in the immunopathogenesis of psoriasis. For example, IL-23 is a regulatory cytokine with a major role in the late-stage maturation and differentiation of T helper 17 lymphocytes, which are important in psoriatic inflammation. IL-23 has been found to be overexpressed in psoriatic lesions. Targeting these cytokines has demonstrated promise in the treatment of psoriasis and psoriatic arthritis.

Save to your areas of interest